Euroopan unioni - suomi - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Suomi - suomi - Fimea (Suomen lääkevirasto)

as grindeks (jsc grindeks) - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 100 mg - sitagliptiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

as grindeks (jsc grindeks) - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg - sitagliptiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

as grindeks (jsc grindeks) - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 25 mg - sitagliptiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

zentiva, k.s. - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 100 mg - sitagliptiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

zentiva, k.s. - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg - sitagliptiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

zentiva, k.s. - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 25 mg - sitagliptiini

Euroopan unioni - suomi - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Suomi - suomi - Fimea (Suomen lääkevirasto)

avansor pharma oy - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 100 mg - sitagliptiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

avansor pharma oy - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg - sitagliptiini